secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001193125-25-002165
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway
---------------------------------------------------------------------

- Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.
- Estimated restructuring charges of $5M to $6M, mostly severance, recorded in Q1 2025.
- Cash payments of ~$5M starting Q1 2025; cash runway extended into Q2 2026.
- Company to prioritize CX-2051 (EpCAM PROBODY ADC) and support research collaborations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/0001193125-25-002165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525002165/d909597d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-002165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer